(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
7 October 2004 (07.10.2004)

PCT

(10) International Publication Number
WO 2004/085421 A2

(51) International Patent Classification⁷: C07D 333/36, 417/04, 233/54, A61K 31/445

(21) International Application Number: PCT/GB2004/001330

(22) International Filing Date: 26 March 2004 (26.03.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0306907.7 26 March 2003 (26.03.2003) GB

(71) Applicants *(for all designated States except US)*: ANGIOGENE PHARMACEUTICALS LIMITED [GB/GB]; The Magdalen Centre, The Oxford Science Park, Oxfordshire OX4 4GA (GB). GRAY LABORATORY CANCER RESEARCH TRUST [GB/GB]; PO Box 100, Mount Vernon Hospital, Northwood, Middlesex HA6 2JR (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: DAVIS, Peter, David [GB/GB]; Angiogene Pharmaceuticals Limited, The Magdalen Centre, Oxford Science Park, Oxfordshire OX4 4GA (GB). NAYLOR, Matthew, Alexander [GB/GB]; The Gray Cancer Institute, PO Box 100, Mount Vernon Hospital, Northwood, Middlesex HA6 2JR (GB). THOMSON, Peter [GB/GB]; The Gray Cancer Institute, PO Box 100, Mount Vernon Hospital, Northwood, Middlesex HA6 2JR (GB). EVERETT, Steven, Albert [GB/GB]; The Gray Cancer Institute, PO Box 100, Mount Vernon Hospital, Northwood, Middlesex HA6 2JR (GB). STRATFORD, Michael, Richard, Lacey [GB/GB]; The Gray Cancer Institute, PO Box 100, Mount Vernon Hospital, Northwood, Middlesex HA6 2JR (GB). WARDMAN, Peter [GB/GB]; The Gray Cancer Institute, P.O. Box 100, Mount Vernon Hospital, Northwood, Middlesex HA6 2JR (GB).

(74) Agent: SRINIVASAN, Ravi, Chandran; J.A. Kemp & CO, 14 South Square, Gray's Inn, London WC1R 5JJ (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: BIOREDUCTIVELY-ACTIVATED PRODRUGS



(1)

(2)



(3)

(57) Abstract: The present invention relates to a compound of formula (1), or a pharmaceutically acceptable salt thereof, wherein: Ar is a substituted aryl or heteroaryl group bearing at least one nitro or azido group or is a group of formula (2) or (3) wherein R_1, and R_2, which may be the same or different are independently optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, aryl, COR_3 or, together with the intervening carbon atom, form an optionally substituted heterocycloalkyl or carbocyclic ring ; L is -OC(O)- or -OP(O)(OR_6)-; n is0or1 ;X is O, S, NR_7 or a single covalent bond; R_3 is OR_4 or NR_4R_5; R_4, R_5, R_6 and R_7 are each independently hydrogen or optionally substituted alkyl or, where R_7 is NR_4R_5, R_4 and R_5 can be joined to form, together with the intervening nitrogen atom, a heterocycloalkyl ring; R_8 is hydrogen, alkoxy or dialkylaminoalkyl; R_9 is optionally substituted alkyl; Rio is hydrogen, alkyl, alkoxy or dialkylaminoalkyl; R_{11} and R_{12} are independently hydrogen, alkyl, alkoxy, thioalkoxy, amino, alkylamino, dialkylamino, morpholino, piperidino,piperazino or l=aziridinyl; A is an optionally substituted aryl or heteroaryl ring; and Dr is a moiety such that DrXH represents a cytotoxic or cytostatic compound.

WO 2004/085421 A2